Form D · Biotechnology

DILON TECHNOLOGIES INC

Newport News, VA · CIK 0001047810

Offering snapshot reported Mar 11, 2026 · SEC filing

Reported sold
$8.06M
Offering amount: $10.4M
Investors reported
184
Form D · investor count
Minimum accepted
$5K
Reported outside-investor minimum
First sale
May 23, 2025
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$4.03M$8.06MJul 8, 2025: $1,889,000.00Jul 8, 2025Mar 11, 2026: $8,056,500.00Mar 11, 2026

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$1,889,000 → $8,056,500
  • Reported investors46 → 184

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 11, 2026Amendment$8,056,500$6,167,500vs Jul 8, 2025184SEC filing
Jul 8, 2025Initial$1,889,000No comparison46SEC filing
Jan 14, 2025Amendment$21,098,500$16,413,500vs Jan 30, 2024148SEC filing
Jan 30, 2024Initial$4,685,000No comparison69SEC filing
Apr 21, 2023Initial$2,727,000No comparison17SEC filing
Oct 11, 2022Initial$4,615,000No comparison39SEC filing
Feb 24, 2022Amendment$4,090,000$2,160,000vs Dec 3, 202149SEC filing
Dec 3, 2021Initial$1,930,000No comparison22SEC filing
Feb 8, 2018Amendment$5,137,750$3,284,750vs Jan 19, 201881SEC filing
Jan 19, 2018Initial$1,853,000No comparison34SEC filing
Dec 31, 2013Initial$3,953,200No comparison107SEC filing
Nov 15, 2011Amendment$1,920,000$720,000vs Sep 13, 201120SEC filing
Sep 13, 2011Amendment$1,200,000$325,000vs Mar 30, 20114SEC filing
Mar 30, 2011Amendment$875,000$570,000vs Feb 22, 201139SEC filing
Feb 22, 2011Amendment$305,000-$109,000vs Nov 24, 20109SEC filing
Nov 24, 2010Amendment$414,000-$2,540,000vs Sep 1, 20104SEC filing
Sep 1, 2010Amendment$2,954,000$779,000vs Apr 15, 2010196SEC filing
Apr 15, 2010Amendment$2,175,000$477,800vs Jul 2, 2009196SEC filing
Jul 2, 2009Amendment$1,697,200$1,036,400vs Feb 26, 200973SEC filing
Jun 29, 2009Initial$749,500No comparison16SEC filing
Feb 26, 2009Amendment$749,500No comparisonNot reportedSEC filing
Feb 26, 2009Amendment$660,800No comparisonNot reportedSEC filing
Nov 12, 2008Initial$0No comparisonNot reportedSEC filing
Nov 12, 2008Amendment$0No comparisonNot reportedSEC filing
Nov 12, 2008Initial$0No comparisonNot reportedSEC filing
Oct 11, 2007PaperNot reportedNo comparisonNot reportedSEC filing
Apr 20, 2006PaperNot reportedNo comparisonNot reported

Offering details

Securities
Equity, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$645K
Finders' fees
$0
Form D file number
021-550924

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Michael N. Taglich1343730Taglich Brothers, Inc. · CRD 29102
Robert F. Taglich1539988Taglich Brothers, Inc. · CRD 29102
Taglich Brothers, Inc.29102

Source: Form D, filed Mar 11, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Francis Bissaillon Director
Rachel F. Brem Director
James Diamonstein Director
Lee H Fairchild Executive
John Reyes Guerra Executive
Tim Jette Executive
Douglas Kieper Executive
Pjerin Luli Executive
George N. Makhoul Director, Executive
Nancy F. Morter Executive
Robert G. Moussa Director
Mark H. Ravich Director
Vijay Singh Executive
Thomas G Sullivan Director
Michael N. Taglich Director
Robert Taglich Director
Michael W. Tiller Executive
Benjamin Welch Executive
W Scott Yarde Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
701 Mariners Row Suite 200
Newport News, VA, 23606